Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 3, 1997, Pages 213-226

  Court, Michael H ^a   Von Moltke, Lisa L ^a   Shader, Richard I ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chlorzoxazone; CYP2E1; cytochrome P450; diethyldithiocarbamate; in vitro; microsomes; oxidative biotransformation

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; NONHUMAN;

AGED; ANIMALS; ANTIDOTES; BIOTRANSFORMATION; CATS; CATTLE; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DITIOCARB; DOGS; ENZYME INHIBITORS; FEMALE; FERRETS; HORSES; HUMANS; MACACA FASCICULARIS; MICE; MICROSOMES, LIVER; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; NADP; RABBITS; RATS; SPECIES SPECIFICITY; SWINE;

EID: 0030894106     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199704)18:3<213::AID-BDD15>3.0.CO;2-0     Document Type: Article

References (33)

1. D. R. Koop, Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J., 6, 724-730 (1992).
2. R. Zand, S. D. Nelson, J. T. Slattery, K. E. Thummel, T. F. Kalhorn, S. P. Adams and J. M. Wright, Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin. Pharm. Ther., 54, 142-149 (1993).
3. E. D. Kharasch and K. E. Thummel, Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology, 79, 795-807 (1993).
4. E. D. Kharasch, D. C. Hankins and K. E. Thummel, Human kidney methoxyflurane and sevoflurane metabolism. Anesthesiology, 82, 689-699 (1995).
5. F. P. Guengerich, D.-H. Kim and M. I. Iwasaki, Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 4, 168-179 (1991).
6. X. Ding, D. R. Koop, B. L. Crump and M. J. Coon, Immunochemical identification of cytochrome P450 isozyme 3a (P450ALC) in rabbit nasal and kidney microsomes and evidence for differential induction by alcohol. Mol. Pharmacol., 30, 370-378 (1986).
7. V. Longo and M. Ingelman-Sundberg, Acetone-dependent regulation of cytochromes P4502E1 and P4502B1 in rat nasal mucosa. Biochem. Pharmacol., 46, 1945-1951 (1993).
8. M. Warner and J.-A. Gustafsson, Effect of ethanol on cytochrome P450 in the rat brain. Proc. Nat. Acad. Sci. USA, 91, 1019-1023 (1994).
9. Y. Funae, S. Imaoka and N. Shimojo, Purification and characterization of diabetes-inducible cytochrome P-450. Biochem. Int., 16, 503-509 (1988).
10. D. E. Salazar, C. L. Sorge and G. B. Corcoran, Obesity as a risk factor for drug-induced organ injury. VI. Incresed hepatic P450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat. Biochem. Biophys. Res. Commun., 157, 315-320 (1988).
11. N. Tindberg and M. Ingelman-Sundberg, Cytochrome P-450 and oxygen toxicity. Oxygen-dependent induction of ethanol-inducible cytochrome P-450 (IIE1) in rat liver and lung. Biochemistry, 28, 4499-4504 (1989).
12. B. J. Song, R. L. Veech and P. Saenger, Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J. Clin. Endocrinol. Metab., 71, 1036-1040 (1990).
13. M. Morimoto, A.-L. Hagbjork, A. A. Nanji, M. Ingelman-Sundberg, K. O. Lindros, P. C. Fu, E. Albano and S. W. French, Role of cytochrome P4502E1 in alcholic liver disease pathogenesis. Alcohol, 10, 459-464 (1993).
14. C. Girre, D. Lucas, E. Hispard, C. Menez, S. Dally and J.-F. Menez, Assessment of cytochrome P-4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem. Pharmacol., 47, 1503-1508 (1994).
15. D. O'Shea, S. N. Davis, R. B. Kim and G. R. Wilkinson, Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin. Pharm. Ther., 56, 359-367 (1994).
16. R. Peter, R. Böcker, P. H. Beaune, M. Iwasaki, F. P. Guengerich and C. S. Yang, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450 IIE1. Chem. Res. Toxicol., 3, 566-573 (1990).
17. E. D. Kharasch, K. E. Thummel, J. Mhyre and J. H. Lillibridge, Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin. Pharm. Ther., 53, 643-650 (1990).
18. V. R. Twele and G. Spiteller, Identifizierung von Chlorozoxazon-Metaboliten im menschlichen Urin. Arzneim. Forsch., 32, 759-763 (1982).
19. W. Tassaneeyakul, D. J. Birkett, M. E. McManus, M. E. Veronese, T. Andersson, R. H. Tukey and J. O. Miners, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 47, 1767-1776 (1994).
20. L. L. von Moltke, D. J. Greenblatt, S. X. Duan, J. S. Harmatz and R. I. Shader, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol., 34, 1222-1227 (1994).
21. L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, S. X. Duan, J. S. Harmatz and R. I. Shader, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake inhibitor antidepressants, ketoconazole, and quinidine. Br. J. Clin. Pharm., 38, 23-31 (1994).
22. L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, S. X. Duan, J. S. Harmatz and R. I. Shader, Inhibition of desipramine hydroxylation in vitro by serotonin-uptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict interactions in vivo. J. Pharmacol. Exp. Ther., 268, 1278-1283 (1994).
23. L. L. von Moltke, D. J. Greenblatt, M. H. Court, S. X. Duan, J. S. Harmatz and R. I. Shader, Inhibition of alprazolam and desipramine metabolism in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin-reuptake inhibitor antidepressants. J. Clin. Psychopharm., 15, 125-131 (1995).
24. H. Akaike, An information criterion. Math. Sci., 14, 5-9 (1976).
25. W. Tassaneeyakul, M. E. Veronese, D. J. Birkett, F. J. Gonzalez and J. O. Miners, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal techniques. Biochem. Pharmacol., 46, 1975-1981 (1993).
26. W. Tassaneeyakul, M. E. Veronese, D. J. Birkett and J. O. Miners, High-performance liquid chromatography assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. J. Chromatogr., 616, 73-78 (1993).
27. H. Yamazaki, Z. Guo and F. P. Guengerich, Selectivity of cytochrome P-4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab. Disposit., 23, 438-440 (1995).
28. H. Boxenbaum, Evolutionary biology, animal behavior, fourth-dimensional space, and the Raison d'Etre of drug metabolism and pharmacokinetics. Drug Metab. Rev., 14, 1057-1097 (1983).
29. G. J. Dutton, Glucuronidation of Drugs and Other Compounds, CRC Press, Inc., Boca Raton, FL, 1980, p. 128.
30. V. Carriere, T. Goasduff, D. Ratanasavanh, F. Morel, J.-C. Gautier, A. Guillouzo, P. Beaune and F. Berthou, Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem. Res. Toxicol., 6, 852-857 (1993).
31. D. J. Newton, R. W. Wang and A. Y. H Lu, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Disposit., 23, 154-158 (1995).
32. T. K. H. Chang, F. J. Gonzalez and D. J. Waxman, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 311, 437-442 (1994).
33. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui and F. P. Guengerich, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423 (1994).